Friday, October 17, 2014

Best Canadian Companies To Watch In Right Now

Jim Grant thinks that the Federal Reserve and central banks around the world have wildly overdone the easy money policies that followed the 2008 financial crisis.

Today Grant thinks there is a great distortion if not a bubble in high yield "junk" bonds where rates do not nearly compensate for the risk involved.

As for stocks he likes, Grant is truly contrarian. He recommends Russian gas giant Gazprom (MIC:RTGZ) which sells at a price to earnings ratio of 2.5 times and has a dividend yield of 5% with only a 15% payout ratio.

About the author:Canadian Valuehttp://valueinvestorcanada.blogspot.com/ Currently 0.00/512345

Rating: 0.0/5 (0 votes)

Subscribe via Email Subscribe RSS

Top 5 Beverage Companies To Invest In 2015: Tim Hortons Inc.(THI)

Tim Hortons Inc. develops, franchises, and operates quick service restaurants primarily in Canada and the United States. Its restaurants serve coffee and other hot and cold beverages, baked goods, sandwiches, soups, and other food products. As of April 03, 2011, the company and its restaurant owners operated 3,169 restaurants in Canada and 613 restaurants in the United States under the Tim Hortons name; and had 274 primarily self-serve licensed locations in the Republic of Ireland and the United Kingdom Tim Hortons Inc. was founded in 1964 and is based in Oakville, Canada.

Advisors' Opinion:
  • [By Ben Levisohn]

    Burger King Worldwide (BKW) has risen 3.2% to $33.45 after Warren Buffett said he would help finance its merger with Tim Hortons (THI). Tim Hortons has leaped 10% to $82.55.

Best Canadian Companies To Watch In Right Now: Talisman Energy Inc.(TLM)

Talisman Energy Inc., an upstream oil and gas company, engages in the exploration, development, production, transportation, and marketing of crude oil, natural gas, and natural gas liquids. It primarily operates in North America, the North Sea, and southeast Asia. The company was founded in 1925 and is headquartered in Calgary, Canada.

Advisors' Opinion:
  • [By Bruce Kennedy]

    The EIA examined annual reports from 42 oil and natural gas companies, from giants like Brazil's Petrobras (NYSE: PBR) and ExxonMobil (NYSE: XOM) to smaller firms like Talisman Energy (NYSE: TLM) and Encana (NYSE: ECA) ��companies that reportedly made up about 40 percent of non-OPEC production last year, and that had combined market capitalization of over $2.4 trillion.

  • [By Ben Levisohn]

    Talisman Energy (TLM) has fallen 3% to $10.37 on reports that discussions with Repsol about a potential asset sale have stalled.

    Tiffany (TIF) has risen 2.6% to $103.40 after the luxury retailer easily topped earnings and revenue forecasts and lifted its full year guidance.

  • [By Monica Gerson]

    Shares of Talisman Energy (NYSE: TLM) jumped more than 8% in after-hours trading after Carl Icahn disclosed a stake in the company. Talisman Energy shares surged 8.94% to $13.89 in the after-hours trading session.

  • [By Value Digger]

    Manitok's competitive advantage is its management team, who knows well where the shallow opportunities exist, from years of bypassing many conventional reservoirs and drilling deeper targets for Talisman Energy (TLM).

Best Canadian Companies To Watch In Right Now: Silvercorp Metals Inc(SVM)

Silvercorp Metals Inc. engages in the acquisition, exploration, development, and operation of silver mineral properties in China and Canada. The company holds interests in four silver, lead, and zinc mines, including the Ying Project, the HPG Project, the TLP Project, and the LM Project at the Ying Mining Camp in the Henan Province of China. It also holds interests in the GC Project, a silver, lead, and zinc mine in the Guangdong Province; and the BYP gold, lead, and zinc mine project in Hunan province, as well as the Silvertip silver, lead, and zinc mine project in northern British Columbia, Canada. The company was formerly known as SKN Resources Ltd. and changed its name to Silvercorp Metals Inc. in May 2005. Silvercorp Metals Inc. is headquartered in Vancouver, Canada.

Advisors' Opinion:
  • [By Selena Maranjian]

    Silvercorp Metals (NYSE: SVM  ) shed 50%, but that leaves it yielding 3.1% -- and it's even earning more than it's paying out, which is promising. The company,�China's biggest primary silver producer, has been in the news as an alleged scammer as well as a possible scamming victim. (It's worth noting that it has been up front about problems, rather than evading them.) In its latest quarter, net income fell 25%, due in large part to falling silver prices, but its silver production was up 17% and gold up 42%. (It produces far less gold than silver, and it also mines lead and zinc.)

  • [By Lisa Levin]

    Silvercorp Metals (NYSE: SVM) shares fell 1.30% to touch a new 52-week low of $2.19. Silvercorp's PEG ratio is 5.18.

    Bancolombia SA (NYSE: CIB) shares touched a new 52-week low of $47.94. Bancolombia's trailing-twelve-month ROA is 1.45%.

  • [By Lisa Levin]

    Silver: This industry jumped 2.71% by 10:40 am. The top performer in this industry was Silvercorp Metals (NYSE: SVM), which rose 5%. Silver futures jumped 3.28% to trade at $20.01 an ounce.

Best Canadian Companies To Watch In Right Now: Valeant Pharmaceuticals International Inc(VRX)

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. It offers Wellbutrin XL to treat depressive disorders; Xenazine to treat chorea associated with Huntington?s disease; CeraVe to rebuild and repair skin barrier; and Kinerase, a cosmetic product. The company also provides Zovirax ointment to treat initial genital herpes; Xerese to treat recurrent herpes labialis; Elidel to treat atopic dermatitis; and Acanya and Atralin gels to treat acne vulgaris. In addition, it offers Cesamet to treat nausea and vomiting associated with cancer chemotherapy; Tiazac XC to treat hypertension and angina; Wellbutrin to treat depressive illness; Sublinox to treat insomnia; and Lodalis to treat hypercholesterolemia. Further, the company provides Cold-FX to strengthen immune system; Duromine/Metermine for weight loss; Difflam to treat sore throa ts; and Duro-Tuss and Rikodeine to treat dry and chesty cough, as well as various branded generics for treatments, including antibiotics, treatments for cardiovascular and neurological diseases, antifungal medications, and diabetic therapies. Additionally, it offers Bisocard to treat hypertension and angina pectoris; Flucinar, a corticosteroid ointment; and Sachol mouth ulcer gel; Bedoyecta to treat neurotic pain; M.V.I., a hospital dietary supplement for trauma and burns; Tandene to treat fever and headache; Melleril to treat anxiety and depression; and products for therapeutic classes, such as vitamin deficiency, antibacterials, and dermatology. It markets its products in the United States, Canada, Australia, New Zealand, Europe, Latin America, southeast Asia, and South Africa. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1960 and is headquartered in M ississauga, Canada.

Advisors' Opinion:
  • [By Vera Yuan]

    We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation.From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.Also check out: Diamond Hill Capital Undervalued Stocks Diamond Hill Capital Top Growth Companies Diamond Hill Capital High Yield stocks, and Stocks that Diamond Hill Capital keeps buying Currently 0.00/512345

    Rating: 0.0/5 (0 votes)

  • [By Tim Brugger]

    Quebec-based Valeant Pharmaceuticals (NYSE: VRX  ) and U.S.-based Bausch & Lomb have entered into a definitive agreement whereby Valeant will purchase privately held Bausch & Lomb for a total of $8.7 billion in cash, the compannies announced today.

  • [By Selena Maranjian]

    For example, consider Lone Pine Capital, founded by Steve Mandel�in 1997. Lone Pine is one of the biggest hedge fund companies, and it has reportedly outperformed�the S&P 500 handily since inception. Its reportable stock portfolio totaled $23 billion�in value as of March 31, 2014. According to its recently released 13F statement, Lone Pine established or added to positions in Jazz Pharmaceuticals plc (NASDAQ: JAZZ  ) , SouFun Holdings Ltd (NYSE: SFUN  ) , and Valeant Pharmaceuticals International (NYSE: VRX  ) .

  • [By Jayson Derrick]

    This morning, Valeant Pharmaceuticals (NYSE: VRX) reported its second quarter results. The company announced an EPS of $1.91, beating the consensus estimate of $1.90. Revenue of $2.00 billion missed the consensus estimate of $2.04 billion. Net income for the quarter rose to $122.0 million from $10.8 million in the same quarter a year ago, as the company saw an 86 percent growth in revenue driven by strong growth in almost every business category. Same-store organic product sales growth was 4 percent in the quarter, while pro forma organic growth was 8 percent. Europe saw a same-store sales organic growth of 13 percent, Asia saw a same-store sales organic growth of 17 percent and the U.S. contact lens business helped contribute a 12 percent organic growth in the U.S. Valeant also released a presentation detailing its expectations through 2016, assuming it acquires Allergan. (NYSE: AGN) Valeant lowered its 2014 guidance to reflect the impact of a sale of assets to Nestle as the company unloaded products that compete with Allergan's. Valeant guided toward 2015 sales of $9.3 billion, ahead of the consensus estimate of $8.9 billion. However, Valeant's 2015 EPS guidance of $9.65 was nearly $1 below the consensus estimate. Shares of Valeant lost 6.71 percent, closing at $117.39.

No comments:

Post a Comment